Literature DB >> 2995817

Expression of insulin-like growth factor-II transcripts in Wilms' tumour.

A E Reeve, M R Eccles, R J Wilkins, G I Bell, L J Millow.   

Abstract

Wilms' tumour probably arises from embryonal kidney cells and occurs in both hereditary and sporadic forms. Knudson and Strong have suggested that both forms of the disease are initiated by two mutational events. In the case of the inherited form, cytogenetic evidence indicates that a germline deletion of chromosome band 11p13 may correspond to one of the two mutations. DNA mapping evidence is consistent with the notion that the tumour susceptibility gene (Wg) on chromosome 11 is actually recessive. Comings has proposed that the dominantly inherited tumours may arise by the inactivation or loss of a diploid pair of regulatory genes which normally suppress the expression of a structural transforming gene (Tg). It has recently been suggested that the N-myc oncogene may serve as a transforming gene in retinoblastoma, although no such gene has yet been identified in Wilms' tumour. We now report that in four cases of Wilms' tumour, insulin-like growth factor-II (IGF-II) transcripts are highly elevated compared with the adjacent normal kidney. In addition, we have mapped the gene for IGF-II to chromosome band 11p14.1, which is in the immediate vicinity of Wg. These findings suggest that IGF-II may be involved in the aetiology of Wilms' tumour.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2995817     DOI: 10.1038/317258a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  77 in total

Review 1.  renal tumors and tumor-like lesions in pediatric patients.

Authors:  J M Kissane; L P Dehner
Journal:  Pediatr Nephrol       Date:  1992-07       Impact factor: 3.714

2.  IGF-II dependent autocrine growth in cell lines derived from renal tumours of childhood.

Authors:  W Zumkeller; A Mahmood; R Dellow; P N Schofield
Journal:  Clin Mol Pathol       Date:  1995-12

3.  Developmental pattern of growth factor production in chick embryo limb buds.

Authors:  J Smith; J C McLachlan
Journal:  J Anat       Date:  1989-08       Impact factor: 2.610

4.  Identification of a novel transcription unit in the human insulin-like growth factor-II gene.

Authors:  K Ikejiri; T Wasada; K Haruki; N Hizuka; Y Hirata; M Yamamoto
Journal:  Biochem J       Date:  1991-12-01       Impact factor: 3.857

5.  Antibody to type I insulinlike growth factor receptor inhibits growth of Wilms' tumor in culture and in athymic mice.

Authors:  T Gansler; R Furlanetto; T S Gramling; K A Robinson; N Blocker; M G Buse; D A Sens; A J Garvin
Journal:  Am J Pathol       Date:  1989-12       Impact factor: 4.307

6.  Development of targeted therapy for a broad spectrum of solid tumors mediated by a double promoter plasmid expressing diphtheria toxin under the control of IGF2-P4 and IGF2-P3 regulatory sequences.

Authors:  Doron Amit; Sagi Tamir; Abraham Hochberg
Journal:  Int J Clin Exp Med       Date:  2013-01-26

7.  novH: differential expression in developing kidney and Wilm's tumors.

Authors:  G Chevalier; H Yeger; C Martinerie; M Laurent; J Alami; P N Schofield; B Perbal
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

8.  Parental allele specific methylation of the human insulin-like growth factor II gene and Beckwith-Wiedemann syndrome.

Authors:  H Schneid; D Seurin; M P Vazquez; M Gourmelen; S Cabrol; Y Le Bouc
Journal:  J Med Genet       Date:  1993-05       Impact factor: 6.318

9.  Normal dosage of the insulin and insulin-like growth factor II genes in patients with the Beckwith-Wiedemann syndrome.

Authors:  R A Spritz; D Mager; R M Pauli; R Laxova
Journal:  Am J Hum Genet       Date:  1986-08       Impact factor: 11.025

10.  Molecular analysis of patients with Wiedemann-Beckwith syndrome. I. Gene dosage on the short arm of chromosome 11.

Authors:  A Nyström; W Engström; J Cheetham; P N Schofield
Journal:  Eur J Pediatr       Date:  1992-07       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.